Canadians are focused on keeping their jobs and paying their bills, as they continue to deal with the impacts of COVID-19. That’s why the Government of Canada has put jobs and workers first, in our approach to support businesses during this challenging time.
May 19, 2020 – Ottawa The Prime Minister, Justin Trudeau, today announced an expansion to the eligibility criteria for the Canada Emergency Business Account (CEBA) to include many owner-operated small businesses. This extended measure will help small businesses protect the jobs that Canadians rely on.
CIIP is pleased to announce its collaboration with NRC-IRAP on the EUREKA call for proposal.
Variational AI Inc. is pleased to announce a new project using their novel artificial intelligence technology to rapidly identify existing drugs with a high probability of being efficacious in combatting COVID-19.
Products made by Vancouver’s STEMCELL Technologies are now being used in over 30 COVID-19 studies worldwide. These studies are focusing on areas ranging from diagnostics and treatments to vaccine development and future prevention.
The MSFHR COVID-19 Research Response Fund opens today (April 6) with the first of several funding calls for BC researchers.
The SARS-CoV-2 (COVID-19) pandemic is impacting the daily lives of everyone around the world. We are isolated within our communities, we are exceeding the capacity of our health systems, and we are struggling to keep pace with the rapidness of the outbreak. But together, we can get through this. And together, we can innovate to make a difference.
Members of Innovative Medicines Canada (IMC) are continuing their efforts in the fight against COVID-19 by donating 100,000 N95 masks for front-line healthcare workers battling the virus.
OutSystems announced that STEMCELL Technologies has launched its “My Status” app to help keep STEMCELL staff safe during the COVID-19 pandemic.
Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a clinical-stage biopharmaceutical company, today provided a corporate update in the context of the developing situation with the COVID-19 pandemic.
Curiox Biosystems in conjunction with STEMCELL Technologies today announced a new system that will help researchers develop vaccines to SARS-CoV-2, the virus that causes COVID-19.
Bold Therapeutics, a clinical-stage biopharmaceutical company developing novel anti-cancer therapies, announced that recent developments have suggested the potential utility of its lead drug BOLD-100 as a novel antiviral agent.
Genome BC is today launching a rapid response funding program to invest in promising research and innovation projects with the real potential to address urgent challenges related to the COVID-19 pandemic.
Canada’s largest biotechnology company, Vancouver’s STEMCELL Technologies, has been making significant contributions to the fight against COVID-19.
The global outbreak of the novel coronavirus (COVID-19) is an issue of growing concern around the world. The innovative pharmaceutical industry is working around the clock to find solutions to treat those infected by the virus and to prevent it from spreading.
As Canada responds to the global COVID-19 pandemic, some Canadians have expressed concern that they may not have access to the medicines they need, when they need them.
AbCellera And Lilly Will Select From 500+ Unique Antibodies Isolated From One Of The First U.S. Patients Who Recovered From COVID-19 To Create Antibody Therapeutics For Treatment And Prevention Of COVID-19